Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

MDGL reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price action shows significant volatility around earnings, with an average absolute Day 0 move of 10.51% and Day +1 follow-through averaging 5.66%. The stock has demonstrated a tendency for large initial reactions, with six of the past eight earnings events producing Day 0 moves exceeding 7% in magnitude.

The direction has been mixed but recently more positive: the most recent report (May 2026) produced a +7.42% Day 0 gain, while the prior three quarters showed a -11.11% decline (February 2026), a +7.83% gain (November 2025), and a +8.59% gain (August 2025). The largest moves occurred in late 2024 during the early Rezdiffra launch phase, with October 2024 delivering a massive +20.10% Day 0 move followed by +23.23% on Day +1.

The Day +1 follow-through has been more muted on average (5.66%) but can be substantial, particularly when the initial reaction is positive. The November 2025 and October 2024 reports both saw strong continuation, while other quarters showed reversals or consolidation. The wide Day 0 ranges—averaging 11.04%—indicate high intraday volatility regardless of closing direction, suggesting investors should prepare for significant price swings in both directions as the market digests results and guidance.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.04% expected move for the upcoming earnings, which is substantially below the 10.51% average absolute Day 0 move from recent history. This suggests options traders may be underpricing potential volatility, particularly given MDGL's pattern of double-digit moves in five of the past eight reports. The $27.54 expected move implies a trading range of $519.34 to $574.42, which may prove conservative if the company delivers significant guidance surprises on the path to profitability.

Part 3: What Analysts Are Saying

Analyst sentiment on MDGL is overwhelmingly bullish, with the consensus rating at 4.70 out of 5.00—firmly in Strong Buy territory. The current breakdown shows 17 Strong Buy ratings, zero Moderate Buys, 3 Hold ratings, and zero Sell ratings among 20 analysts covering the stock. This represents an improved sentiment trend, with Strong Buy recommendations increasing from 16 to 17 over the past month while the average recommendation ticked up from 4.68 to 4.70.

The mean price target of $669.50 implies 22% upside from the current price of $546.88, with a wide range of expectations spanning from a low target of $553 (just 1% upside) to a high target of $964 (76% upside). The high target from Barclays reflects particularly aggressive optimism about Rezdiffra's commercial potential and the company's ability to capture the MASH treatment market.

Recent analyst activity has been notably positive, with multiple firms raising price targets in 2026. Truist lifted its target to $709 in May, Barclays initiated coverage with the Street-high $964 target in January, and B. Riley upgraded to Buy from Neutral in February while raising its target to $422. Even previously cautious BofA Securities upgraded from Underperform to Neutral in November 2025, citing Rezdiffra's better-than-expected performance. The concentration of Strong Buy ratings and the improved sentiment trend suggest analysts see the current valuation as attractive relative to the company's growth trajectory, particularly as it approaches the critical inflection point toward profitability in fiscal 2027.

Part 4: Technical Picture

MDGL enters earnings with strong technical momentum across all timeframes. The Barchart Technical Opinion currently stands at 100% Buy, a significant strengthening from 88% Buy one week ago and 32% Buy one month ago. This dramatic improvement in the signal reflects accelerating bullish momentum as the stock has climbed steadily into the earnings release.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the report
• Medium-term (100% Buy): Bullish reading confirms the uptrend is well-established across intermediate timeframes
• Long-term (100% Buy): Maximum buy signal suggests the longer-term trend structure remains firmly positive

Trend Characteristics: The trend is characterized as Soft but Strengthening, indicating momentum is building but may not yet be fully mature, leaving room for further acceleration if results exceed expectations.

The stock is trading at $546.88, positioned above all key moving averages: the 5-day ($544.96), 10-day ($544.39), 20-day ($542.07), 50-day ($517.82), 100-day ($508.48), and 200-day ($506.73). This complete alignment with price above all major moving averages is a classically bullish setup, with the shorter-term averages trending above longer-term averages in proper sequence.

The technical picture is supportive heading into earnings, with the stock in a clear uptrend and no overhead resistance from moving averages. The 8% year-to-date gain and recent acceleration above the $540 level suggest buyers are positioning ahead of the release. However, the "Soft" trend strength designation and the stock's history of volatile post-earnings moves warrant caution—while the setup is constructive, the technical momentum alone may not be sufficient to cushion a disappointing result. The 5.6% cushion above the 50-day moving average provides some support, but given MDGL's tendency for 10%+ earnings moves, a miss could quickly reverse the recent gains. Conversely, a strong beat with positive guidance could propel the stock toward the analyst consensus target zone near $670.